Oppenheimer Starts Celgene (CELG) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Leerink Notes Positive Celgene (CELG) CFO Meeting
November 30, 2016 6:44 AM ESTLeerink Partners analyst Geoffrey Porges said yesterday's Celgene (NASDAQ: CELG) CFO meeting focused on positive trends, confidence in guidance and LT outlook.
Porges commented, "Yesterday as part of our POLARxPRESS biopharma bus tour, we and a group of investors met with Celgenes (CELG, MP) CFO Peter Kellogg and Investor Relations team for an hour to discuss the company's outlook for the myeloma market, US healthcare policy, and long-term strategic assets. The main topics discussed were the impact of Darzalex (daratumumab, JNJ, OP) on Revlimids average duration of therapy and the staging of... More
